Because the astronomical cost of adalimumab puts it in the “specialty drugs” category, most insurers will only cover it at 50-70% after the deductible is met. We are extremely lucky to be in a position where we can technically afford these healthcare costs. While the arrival of generic adalimumab has reduced costs for insurers, it has increased costs for most consumers. When healthcare services are rendered for profit, the only people who win are rich executives, while the rest – especially those with chronic illness – suffer. Allowing insurers to profit off of human suffering is unacceptable, and we must pressure our representatives to act.